|
|
|
A potential therapy for Friedreich's ataxia, a neurodegenerative disease that is caused by gene activation, is described in the October 2006 issue of Nature Chemical Biology.
Frataxin, a protein that protects neurons from cell death caused by free radicals, is 'silenced' in the neurodegenerative disease Friedreich's ataxia. The production of a gene can be regulated by changing the chemical tags attached to nearby histones, or beads that DNA is wrapped around inside the cell. In Friedreich's ataxia, an expansion in the 'noncoding' portion of FXN (the gene encoding frataxin) and modification of the gene's associated histones results in silencing FXN transcription. Gottesfeld and colleagues have identified a class of inhibitors that reverse the silencing in cells in people with Friedreich's ataxia. The inhibitors specifically changed the chemical modifications of the histones around FXN. These compounds now join the handful of therapeutics that activate specific gene transcription in a human disease. Author contact: Joel M Gottesfeld (The Scripps Research Institute, La Jolla, CA, USA)
E-mail: joelg@scripps.edu Abstract available online. (C) Nature Chemical Biology press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|